The NMPA has granted BTD to IBI343 as monotx. for the treatment of advanced G/GEJ adenocarcinoma who are claudin18.2-positive and have progressed after at least 2L of prior systematic treatment
The BTD was based on ongoing P-I trial, evaluating IBI343 monotx. in GC and continue to check efficacy & safety in the registration MRCT. Study results are expected to be published at a upcoming medical conference in 2024
Innovent, soon to initiate registrational P-III (G-HOPE-001) MRCT of IBI343 to treat GC patients who are claudin18.2-positive, HER2-negative
Ref: Innovent | Image: Innovent
Related News:- Innovent Reports Results from the P-II Study of IBI302 for the Treatment of Neovascular Age-related Macular Degeneration (nAMD)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
